focus -WSS

focus

author：fashion 2025-09-03 12:02:31 - browse：8

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： iTeos Therapeutics debuts first data on TIGIT

WSS

Addiction doctors spar with methadone clinics over legislation

AI used to predict Covid

Lab trade group sues FDA to halt regulation of lab

Patients, digital health players weigh in on FTC's data privacy plan

Akili, maker of video game for ADHD, to be acquired for 34 million

Patients, digital health players weigh in on FTC's data privacy plan

focus

focus

focus

Anesthesiologist group: stop taking Ozempic before surgery

Report: NIH

Heart attack and stroke risk calculators need revising

Average age of first period drops to 11.9 years, study shows

Novavax promises a turnaround & Lilly roils the obesity market

Timeline: How the deadly wildfires took over Maui day by day

Bright Health sells Medicare Advantage business to Molina

Novo Nordisk touts Wegovy study, but still struggling with supply

Supreme Court strikes down use of affirmative action

AI used to predict Covid

focus

iTeos Therapeutics debuts first data on TIGIT

Lab trade group sues FDA to halt regulation of lab

Be careful with at

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Illumina slashes 2023 revenue projections yet again

David Sabatini, ex

entertainment

hotspot

explore

focus